Or Eisenberg Biography and Net Worth

Chief Financial Officer of NeuroSense Therapeutics

CFO at NeuroSense Therapeutics.

Mr. Eisenberg is a registered CPA with broad experience in all aspects of public companies in Israel and in the US.
Prior to joining NeuroSense, he served in several financial management positions in the biotech industry, including CFO and acting CEO of Wize Pharma Inc.
Prior to that, Or served as controller of the Katzir Fund Group, following his position as external Chief Financial Officer for a number of public companies whose shares are listed for trading on the TASE.
Mr. Eisenberg began his career as an accountant at Ernst & Young.

B.A. in Economics and Accounting from Haifa University, and Certified Public Accountant.

What is Or Eisenberg's net worth?: The estimated net worth of Or Eisenberg is at least $9.87 million as of June 16th, 2026. Mr. Eisenberg owns 1,504,050 shares of NeuroSense Therapeutics stock worth more than $9,866,568 as of September 14th. This net worth evaluation does not reflect any other investments that Mr. Eisenberg may own. Learn More about Or Eisenberg's net worth.
How do I contact Or Eisenberg?: The corporate mailing address for Mr. Eisenberg and other NeuroSense Therapeutics executives is , , . NeuroSense Therapeutics can also be reached via phone at 972-9799-6183. Learn More on Or Eisenberg's contact information.
Has Or Eisenberg been buying or selling shares of NeuroSense Therapeutics?: Or Eisenberg has not been actively trading shares of NeuroSense Therapeutics within the last three months. Most recently, on Tuesday, June 16th, Or Eisenberg bought 250,000 shares of NeuroSense Therapeutics stock. The stock was acquired at an average cost of $0.80 per share, with a total value of $200,000.00. Following the completion of the transaction, the chief financial officer now directly owns 1,504,050 shares of the company's stock, valued at $1,203,240. Learn More on Or Eisenberg's trading history.
Who are NeuroSense Therapeutics' active insiders?: NeuroSense Therapeutics' insider roster includes Alon Ben-Noon (CEO & Board Member), and Or Eisenberg (Chief Financial Officer). Learn More on NeuroSense Therapeutics' active insiders.
Are insiders buying or selling shares of NeuroSense Therapeutics?: In the last twelve months, NeuroSense Therapeutics insiders bought shares 2 times. They purchased a total of 500,000 shares worth more than $400,000.00. The most recent insider tranaction occured on June, 16th when CEO Alon Ben-Noon bought 250,000 shares worth more than $200,000.00. Insiders at NeuroSense Therapeutics own 27.4% of the company. Learn More about insider trades at NeuroSense Therapeutics.
Information on this page was last updated on 6/16/2026.

Or Eisenberg Insider Trading History at NeuroSense Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/16/2026	Buy	250,000	$0.80	$200,000.00	1,504,050

Or Eisenberg Buying and Selling Activity at NeuroSense Therapeutics

NeuroSense Therapeutics Company Overview

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

Today's Range

Now: $6.56

$5.60

$7.46

50 Day Range

MA: $0.52

$0.33

$0.73

2 Week Range

Now: $6.56

$5.00

$26.64

Volume

31,112 shs

Average Volume

12,092 shs

Market Capitalization

$248.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.6